Stocktoria
Anteris Technologies Global Corp. AVR
Anteris Technologies Global Corp. (AVR) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.9M at a -4921.3% net margin.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AVR | Anteris Technologies Global Corp. | 2/9 | — | — | — |
| NTRB | NutriBand Inc. | 3/9 | -15.84 | — | — |
| CLGN | CollPlant Biotechnologies Ltd | 3/9 | — | — | — |
| FEED | ENvue Medical, Inc. | 2/9 | -6.2 | — | — |
| SPAI | Safe Pro Group Inc. | 4/9 | 9.05 | — | — |
| COCH | Envoy Medical, Inc. | 2/9 | — | — | — |
| CUPR | Cuprina Holdings (Cayman) LTD | 4/9 | -2.57 | — | — |
About Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
FAQ
Is AVR financially healthy?
Anteris Technologies Global Corp.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does AVR pay a dividend?
No, Anteris Technologies Global Corp. does not currently pay a dividend.
How profitable is AVR?
In FY2025, Anteris Technologies Global Corp. had a net margin of -4921.3%.
What is the analyst price target for AVR?
The average Wall-Street price target for Anteris Technologies Global Corp. is $15.33, about 72.9% above the recent price, from 3 analysts (consensus: strong buy).
Is AVR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Anteris Technologies Global Corp.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.